45 results
Page 2 of 3
F-1/A
t3x5us75egh62utlphwt
12 Mar 20
Registration statement (foreign) (amended)
5:15pm
F-1/A
1vj5hhrrd2pwgi5421j
6 Mar 20
Registration statement (foreign) (amended)
5:32pm
6-K
EX-99.1
kxhlwbu qjorolieu
28 Feb 20
Current report (foreign)
9:46am
6-K
EX-99.1
yxyerpae92vhuz7dn6uy
19 Feb 20
Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor
9:32am
F-1
65w2c3o9f82z
18 Feb 20
Registration statement (foreign)
5:15pm
6-K
EX-99.1
fm20eyjsr8l2yx1fl
12 Feb 20
Mereo Biopharma Announces Update on Distribution Related to Contingent Value Rights Following Recent Oncologie Licensing Agreement for Navicixizumab
9:48am
6-K
EX-99.1
tgmsp2r
10 Feb 20
Current report (foreign)
7:20am
6-K
EX-99.1
633x986dmcgwi oac
14 Jan 20
Current report (foreign)
8:40am
6-K
EX-99.1
p80lch0
13 Jan 20
Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab
8:26am
6-K
EX-99.1
q8nqg2 o97z9j21cvk7
22 Nov 19
Current report (foreign)
9:29am
6-K
EX-99.1
zccno aq5
7 Oct 19
Mereo BioPharma Receives FDA Fast Track Designation for Navicixizumab for the Treatment of Heavily Pretreated Ovarian Cancer
12:23pm
6-K
usugyc do9ir8yini9
17 Sep 19
Current report (foreign)
8:06am
6-K
EX-99.1
c39g692erod nt5fgufc
17 Sep 19
Current report (foreign)
8:06am
20-F
bbmf ch8po
29 Apr 19
Annual report (foreign)
4:59pm
6-K
2a3njzknn5rgf0y63
29 Apr 19
Current report (foreign)
12:09pm
424B3
qx5nw8ccpsztopf838n
20 Mar 19
Prospectus supplement
4:58pm
F-4/A
lh5r9xtwq25 kf
15 Mar 19
Registration of securities (foreign) (amended)
5:08pm
425
lg9nc1 jfzr
12 Mar 19
Business combination disclosure
9:27am
425
pge3 ppw3t3n
15 Feb 19
Business combination disclosure
6:50am
425
w3rg3llg3 g0
12 Feb 19
Business combination disclosure
12:00am